Antonina S Rait

20030064514, Apr 3, 2003

Feb 17, 2000

09/423198

EUGEN UHLMANN - GLASHUTTEN, DE
ANUSCHIRWAN PEYMAN - KELKHEIM, DE
DAVID WILLIAM WILL - KRIFTEL, DE
ESTHER CHANG - CHEVY CHASE MD, US
KATHLEEN PIROLLO - ARLINGTON VA, US
ANTONINA RAIT - ARLINGTON VA, US

HOECHST MARION ROUSSEL DEUTSCHLAND GmbH

A61K048/00
C07H021/04

435/375000, 514/044000, 536/023200

The invention relates to a specific modified oligonucleotide complementary to a section of the human Hs-ras gene and mRNA, and its use to specifically regulate, modulate, or inhibit expression of the Ha-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-ras gene, in particular in combination with chemotherapy and radiotherapy. The modified oligodeoxynucleotide according to the invention has the sequence: 5′-TxAxTxTxCxCxGxTxCxAxTx-3′-O—PO—O—R, wherein x is o or s, with the proviso that x is at least 4 times s and at maximum 9 times s and o means a phosphodiester internucleoside linkage, s means a phosphorothioate internucleoside linkage, R means a C-Calkyl group, —(CH-CHO)—(CH)—CHor ——CH(OH)CHO—(CH)—CHwherein n is an integer from 1 to 6, m is an integer from 0 to 20 and q is an integer from 7 to 20 and A is 2′-deoxyadenosine, G is 2′-deoxyguanosine, C is 2′-deoxycytidine and T is thymadine.

20040241088, Dec 2, 2004

Jan 28, 2004

10/765568

Esther Chang - Potomac MD, US
Kathleen Pirollo - Rockville MD, US
Antonina Rait - Rockville MD, US

Georgetown University - Washington DC

A61K051/00

424/001110

A method for evaluating the efficacy in the body of a mammal of a therapeutic agent which acts to stimulate apoptosis comprises: obtaining a sample of a body tissue in which tumor cells are present or a body fluid from a mammal to be treated with the therapeutic agent which acts to stimulate apoptosis, wherein the tissue or fluid can contain a 17 kDa fragment of Caspase 3, the fragment obtained by specific cleavage of Caspase 3 in vivo; assaying the sample to determine the amount of the 17 kDa fragment of cleaved Caspase 3 present; administering the therapeutic agent to the mammal; obtaining a second sample of said body tissue or body fluid from said mammal; and assaying the second sample to determine the amount of said 17 kDa fragment of cleaved Caspase 3 present; wherein an increase in the amount of the 17 kDa fragment measured in the second sample over the amount measured in the first sample indicates apoptosis stimulation and efficacy of the therapeutic agent.

20050020523, Jan 27, 2005

Dec 11, 2003

10/732218

Eugen Uhlmann - Glashutten, DE
Anuschirwan Peyman - Kelkheim, DE
David Will - Kriftel, DE
Esther Chang - Chevy Chase MD, US
Kathleen Pirollo - Arlington VA, US
Antonina Rait - Arlington VA, US

Aventis Pharma Deutschland GmbH - Frankurt Am Main

A61K048/00
C07H021/02

514044000, 536023100

The invention relates to a specific modified oligonucleotide complementary to a section of the human Ha-ras gene and mRNA, and its use to specifically regulate, modulate or inhibit expression of the HA-ras gene, and its use as a pharmaceutical for the treatment of conditions arising from the abnormal expression of the Ha-Ras gene, in particular in combination with chemotherapy and radiotherapy. The modified oligodeoxynucleotide according to the invention has the sequence 5′-TxAxTxTxCxCxGxTxCxAxT-3′-O—PO—O—R (SEQ ID NO:1), wherein X is an internucleotide linkage of type o or s, with the proviso that x is an s linkage at least 4 times and at most 9 times, and o means a phosphodiester internucleoside linkage, s means a phosphorothioate internucleoside linkage, R means a C-Calkyl group, —(CH—CHO)n-(CH)—CH, or —CH—CH(OH)CHO—(CH)—CHwherein n is an integer from 1 to 6, m is an integer from 0 to 20 and q is an integer from 7 to 20 and A is 2′-deoxyadenosine, G is 2′-deoxyguanosine, C is 2′-deoxycytidine and T is thymidine.

20210205456, Jul 8, 2021

Feb 5, 2021

17/168614

- Washington DC, US
SangSoo KIM - Gaithersburg MD, US
Antonina RAIT - Rockville MD, US

A61K 45/06
A61K 9/127
A61K 9/00

The present invention is in the field of drug delivery, and specifically, cationic liposome-based drug delivery. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of liposomes to tumors, including brain tumors. In embodiments, the liposomes deliver temozolomide across the blood-brain barrier for treatment of primary or metastatic brain tumors. Additional cancers that can be treated with the liposomes include neuroendocrine tumors, melanoma, prostate, head and neck, ovarian, lung, liver, kidney, breast, urogenital, gastric, colorectal, cervical, vaginal, angiosarcoma, liposarcoma, rhabdomyosarcoma, choriocarcinoma, pancreatic, retinoblastoma and other types of cancer. In another embodiment the liposomes deliver melphalan for the treatment of multiple myeloma, other tumors of the blood or other solid tumors. In still other embodiments the liposomes can deliver other drugs such as pemetrexed or irinotecan for treatment of cancer or drugs including atropine for treatment of organophosphate poisoning.

20140120157, May 1, 2014

Sep 18, 2013

14/030563

- Washington DC, US
SangSoo Kim - Gaithersburg MD, US
Antonina Rait - Rockville MD, US

Georgetown University - Washington DC

A61K 47/48
A61K 45/06

424450, 4241781

The present invention is in the field of drug delivery, and specifically, cationic liposome-based drug delivery. In embodiments, this invention provides methods of making ligand-targeted (e.g., antibody- or antibody fragment-targeted) liposomes useful for the delivery of liposomes to tumors, including brain tumors. In embodiments, the liposomes deliver temozolomide across the blood-brain barrier for treatment of primary or metastatic brain tumors. Additional cancers that can be treated with the liposomes include neuroendocrine tumors, melanoma, prostate, head and neck, ovarian, lung, liver, kidney, breast, urogenital, gastric, colorectal, cervical, vaginal, angiosarcoma, liposarcoma, rhabdomyosarcoma, choriocarcinoma, pancreatic, retinoblastoma and other types of cancer. In another embodiment the liposomes deliver melphalan for the treatment of multiple myeloma, other tumors of the blood or other solid tumors. In still other embodiments the liposomes can deliver other drugs such as pemetrexed or irinotecan for treatment of cancer or drugs including atropine for treatment of organophosphate poisoning.